CD274 and non-small cell lung carcinoma: highlighted the potential predictive value of KMT2C for immunotherapeutic benefit in non-squamous NSCLC, and furthermore, the combination of KMT2C and PD-L1 could serve as the best partner for guiding therapeutic decisions based on anti-PD-(L)1 (112).